Open access
Sep 2026
Analysis of clinical features and outcomes in a Chinese cohort with ALK fusion across pan-cancer: a retrospective study
Background ALK fusions are validated oncogenic drivers, yet their molecular heterogeneity and therapeutic implications remain poorly characterized. This study defined the landscape of ALK fusion partners, EML4-ALK variants, and co-mutations and their impact on treatment responses in a large Chinese pan-cancer cohort. M...
Meng Zhang, Yi Feng, Xue Du et al.
· Frontiers in Oncology · 0 citations